Recently, the OpenMediLead platform, focusing on the cardiovascular and cerebrovascular field, officially entered its internal testing phase on WeChat mini-program. The platform centers on the interactive testing of its AI drug discovery engine and AI clinical diagnostic decision-making engine. Utilizing a lightweight mini-program entry point, it conducts real-world scenario verification and collects user feedback, laying a crucial foundation for the next step of officially establishing a closed-loop system between clinical practice and research. It aims to reconstruct a new model of medical and pharmaceutical integration using artificial intelligence technology, facilitating precise diagnosis and treatment of cardiovascular and cerebrovascular diseases and the efficient development of innovative drugs.

OpenMediLead was founded by Li Chengli and his core team. The platform has a clear and firm core value: with the vision of "building an ecosystem of artificial intelligence in medicine and pharmaceuticals", and the mission of "making medical knowledge and pharmaceuticals less difficult and achieving the highest level of medical integration by combining traditional and technological approaches", it always adheres to the original intention of "staying true to its roots and putting people first". It focuses on the cardiovascular and cerebrovascular diseases, a major area of national health needs, and solves the core pain points that have long existed in the industry, such as the disconnect between research and diagnosis, low R&D efficiency, high difficulty in diagnosis and treatment decisions, and high technical barriers.

This WeChat mini-program version, launched for internal testing, is invitation-only and represents the first lightweight entry point for the implementation of OpenMediLead's dual-engine medical intelligence system. Currently, the focus is on completing the interactive verification of the AI drug development and AI clinical diagnosis engines. The AI drug development engine targets the early stages of innovative cardiovascular and cerebrovascular drug development, covering core functions such as innovative target discovery, small molecule generation and optimization, drugability prediction, ADMET precise assessment, and virtual screening. Leveraging high-quality specialist data and advanced algorithm models, it improves the efficiency and success rate of early-stage drug development. The AI clinical diagnosis decision engine, based on real-world clinical scenarios, provides functions such as cardiovascular and cerebrovascular disease risk stratification, assisted diagnosis, personalized treatment plan recommendations, and prognostic assessment. It strictly adheres to clinical guidelines and treatment standards, assisting physicians in improving decision-making efficiency and accuracy.

During the internal testing phase, the platform will comprehensively collect real user feedback from pharmaceutical R&D personnel, clinicians, experts from research institutes, and industry practitioners. The focus will be on verifying the stability of the dual-engine interaction, the rationality of data interoperability, the reliability of model output, and the practicality of scenario implementation. Based on the test results, scientific decisions will be made and optimizations will be optimized and iterated. Ultimately, a two-way closed loop will be achieved, where real clinical needs feed back into drug development and drug development results empower clinical diagnosis and treatment, filling the industry gap in the integration of "research-diagnosis-application" in the cardiovascular field.

OpenMediLead adheres to the principles of scientific rigor, compliance, controllability, explainability, and verifiability in its research and development. It strictly controls the risks of AI applications and data security, rejects exaggerated technology claims and false advertising, and designs all models and functions around real clinical needs and industry research and development pain points to ensure that technological achievements truly serve the industry, healthcare, and patients.

Li Chengli, founder of OpenMediLead, stated that cardiovascular and cerebrovascular diseases are one of the primary threats to the health of Chinese residents. The value of AI technology lies not in its concept, but in its implementation and widespread accessibility. OpenMediLead's dual-engine medical intelligence system lowers the barrier to entry through WeChat mini-programs and achieves deep collaboration between medicine and pharmaceuticals through dual AI engines. Ultimately, it aims to simplify complex medical knowledge and drug development processes with technology, promote the deep integration of traditional medicine and artificial intelligence, and reach a new realm of more efficient, precise, and inclusive medicine, truly putting people first and safeguarding life.

In the future, with internal testing optimization and closed-loop integration, OpenMediLead will continue to deeply cultivate the cardiovascular and cerebrovascular field, constantly iterating its technology, improving its ecosystem, and expanding cooperation. Together with pharmaceutical companies, medical institutions, research institutions, and other partners, it will jointly build an open, collaborative, and inclusive AI-powered medical and pharmaceutical ecosystem, using technological innovation to help implement the Healthy China strategy and safeguard the cardiovascular and cerebrovascular health of the nation.

https://news.yaozh.com/archive/47301.html